Navigation Links
MIT radar technology fights breast cancer

CAMBRIDGE, Mass.--Treating breast cancer with a type of heat therapy derived from MIT radar research can significantly increase the effectiveness of chemotherapy, according to results from the fourth clinical trial of the technique reported online Nov. 25 in the journal Cancer Therapy.

In this study, large tumors treated with a combination of chemotherapy and a focused microwave heat treatment shrunk nearly 50 percent more than tumors treated with chemotherapy alone. The microwave treatment is based on technology originally developed at MIT in the late 1980s as a tool for missile detection.

It appears that heating the tumors drastically increased the effectiveness of the chemotherapy, said Dr. William C. Dooley, director of surgical oncology at the University of Oklahoma and the principal investigator of the study. The tumors shrank faster and died faster using the additional microwave hyperthermia on top of the chemotherapy.

According to the National Cancer Institute, some 178,000 women and 2,000 men were diagnosed with breast cancer in 2007. An estimated 40,000 women and 450 men will die of the disease this year.

In the latest clinical trial, fifteen patients received two microwave heat treatments, known as thermotherapy, along with four rounds of chemotherapy before surgery. The goal was to shrink tumors sufficiently to enable a breast-conserving lumpectomy procedure instead of the expected, and more invasive, mastectomy. Surgeons concluded that fourteen of the tumors shrunk enough for this to be possible.

In 1990, Dr. Alan J. Fenn, a senior staff member at MITs Lincoln Laboratory, adapted the thermotherapy treatment from a system that used focused microwaves to detect missiles and block out interfering enemy signals.

Its a very simple idea that can be applied to the treatment of many different cancers, including breast cancer, Fenn said.

The microwaves, delivered by two applicators placed near the breast, kill the cancerous tissue while preserving normal breast tissue by targeting tumor cells that contain high amounts of both water and ions, Fenn explained. When the microwave energy passes through the tumor, the water molecules begin to vibrate and generate heat through friction. This process eventually elevates the cancer cells to a high fever of at least 108 degrees Fahrenheit in most cases, killing them.

The treatment is well tolerated, said Dr. Mary Beth Tomaselli, medical director at Comprehensive Breast Center in Coral Springs, Fla., and a surgeon who was also a co-investigator in the study. The patients who have gone through it had minimal side effects and positive results.

This is the fourth clinical trial of the therapy since 1999. In a Phase-I safety trial using microwave heat alone, researchers found that both small and large breast tumors could be decreased in size between 30 and 60 percent. In a Phase-II dose-escalation trial for small tumors, scientists increased the amount of heat until 100 percent of the tumor cells were killed, prior to the patients receiving a lumpectomy.

Next, researchers treated similar early-stage tumors and noticed that after the surgical removal, none of the patients had tumor cells remaining at the edge of the incision. This is important because additional breast surgery and/or radiation therapy are often recommended for patients that have cancer cells close to the edge of the lumpectomy surgical margin.

The treatment centers for the latest study, which focused on larger tumors, included Harbor-UCLA Medical Center in Torrance, Calif., the University of Oklahoma in Oklahoma City, Comprehensive Breast Center in Coral Springs, Fla., St. Josephs Hospital in Orange, Calif., and five additional sites. Celsion (Canada) Limited licenses the focused microwave thermotherapy technology from MIT, and has produced 10 clinical systems to date to perform the procedures.

The team has applied for approval for a large-scale clinical trial from Health Canada (the equivalent of the US FDA) and will be applying for the same approval from the FDA. Researchers will then test the treatment in a randomized study of 228 patients who have large breast-cancer tumors. Patients will receive either chemotherapy alone or chemotherapy plus microwave heat treatments at one of six participating medical centers in the United States and Canada.

The patients who have the best results in cancer treatment, at least with breast cancer, are patients who have a sequence of different therapies, including chemotherapy, surgery, radiation, and hormones, said Dr. Hernan I. Vargas, associate professor of surgery at UCLA and lead author of the recent study. Each one of the treatments adds a little bit. The thermotherapy might be one more tool that helps us fight this disease.


Contact: Elizabeth Thomson
Massachusetts Institute of Technology

Related medicine news :

1. Quantum light beams good for fast technology
2. New Smart Technology Makes Patient Data Collection Easier, More Efficient
3. Align Technology Executive to Present at Upcoming Financial Conferences
4. Pioneer Surgical Technology Hires Vice President of New Business Development
5. Purdue researchers develop technology to detect cancer by scanning surface veins
6. Creative Technology Services Enhances its Global Competitiveness with Additional Regulatory Certifications
7. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
8. Patent Reform Legislation Threatens Americas Leadership in Medical Technology Innovation
9. Stevens Health, Technology and Society roundtable: Sept. 19
10. Microbiotic technology developed for microinjection of zebrafish embryos
11. Proven Terumo Coronary Guidewire Technology Is Now Available in the United States
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions ... SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of ... SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates ...
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... the Commission on Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its ... exclusive list of CAAHEP accredited colleges, as only one of twelve colleges and universities ...
(Date:11/27/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk ... Term Support) into its Q-Suite 5.10 product line. , Making the change to ... of Asterisk that will receive not only security fixes, but feature and bug ...
(Date:11/26/2015)... ... 2015 , ... Somu Sivaramakrishnan announced today that he joined ... offers travelers, value and care based Travel Services, including exclusive pricing on a ... cabin upgrades and special amenities such as, shore excursions, discounted fares, travel gifts ...
(Date:11/26/2015)... Mass. (PRWEB) , ... November 26, 2015 , ... ... thorough second medical opinion process, participated in the 61st annual Employee Benefits Conference. ... Plans and took place Sunday, November 8th through Wednesday, November 11th, 2015. The ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda SyMRI ... (MR-bilder) för patienter med multipel skleros ... forskningsavtal med SyntheticMR AB för att kunna ... på sjukhuset. Med SyMRI kan man generera ...
(Date:11/26/2015)... India , November 26, 2015 ... --> adds ... Report" and "Investigation Report on China ... and 2021 forecasts data and information ... . ...
(Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
Breaking Medicine Technology: